CagriSema (cagrilintide + semaglutide)

Also known as Cagrilintide/semaglutide combination.

Research / investigational listing only. This compound is not available for consumer purchase from Cellular Sequence and must not be confused with shop products.

Research / investigational compoundThis compound does not have an established approved therapeutic dosing schedule. Doses below describe those reported in published scientific research and should not be interpreted as a treatment recommendation.

At-a-glance profile

Classification: Investigational amylin + GLP-1 combination
Approval status: Investigational · Not approved for human use
Research status: Investigational / reference listing.
Molecular formula: Insufficient reliable evidence identified.
Molecular weight: Insufficient reliable evidence identified.
Sequence: Fixed-ratio research or trial combination; catalogue ‘CS5/CS10’ blends are not licensed CagriSema.
Primary biological target: Insufficient reliable evidence identified.
Half-life: Insufficient reliable evidence identified.
Routes investigated: Insufficient reliable evidence identified.
Human evidence level: C — Limited or early human evidence

What is it?

A clinical combination concept. Unlicensed mixed vials are not Novo Nordisk trial drug. Not sold.

Mechanism of action

Dual satiety signalling (amylin + GLP-1) in principle.

Potent metabolic and GI effects if both actives are present — still unapproved as a DIY blend.

What is it being studied for?

Obesity pipeline combinations

Investigational findings are not proven clinical benefits unless an authority has labelled that indication.

Evidence level

Overall human evidence grade: C · Limited or early human evidence

Human research

Sponsor trials ≠ grey-market CS10 kits.

Preclinical research

Animal, cell and in-vitro findings are listed separately from human effects.

See cagrilintide and semaglutide.

Doses reported in published research

This section does not provide personalised medical dosing. Values are those reported in papers or protocols. Animal mg/kg doses are not converted to human doses.

Doses reported in human studies

Insufficient reliable evidence identified.

Preclinical / animal study dosing

Insufficient reliable evidence identified.

Pharmacokinetics

Reliable human pharmacokinetic data were not identified for this encyclopaedia entry, or are limited to product information for approved presentations.

Safety

Stacked GI and hypoglycaemia-adjacent risks with quality unknown.

Unknowns. Absence of a published harm signal is not evidence of safety.

Contraindications. Not for human use.

Regulatory status

Not approved as a finished combination vial from research catalogues.

Cellular Sequence does not sell this as a vial, tablet, oil, or injectable. Educational encyclopaedia listing only.

Citations

[1] Encyclopaedia note
Encyclopaedia note

For educational and research reference only. This page summarises published scientific literature and does not constitute medical advice, prescribing information or a recommendation to use an investigational compound. Research doses shown describe doses reported in published studies and are not personalised dosing instructions.

Last reviewed 2026-09-13. Research areas: Metabolic · Compare peptides